Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
M. Kundranda, A. C. Gracian, S. F. Zafar, E. Meiri, J. Bendell, H. Algül, F. Rivera, E. R. Ahn, D. Watkins, U. Pelzer, V. Charu, A. Zalutskaya, G. Kuesters, J. M. Pipas, S. Santillana, V. Askoxylakis, A. H. Ko
Research output: Contribution to journal › Article › peer-review
38Scopus
citations
Fingerprint
Dive into the research topics of 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)'. Together they form a unique fingerprint.